5.54 USD
-0.01 (-0.18%)
5.54 USD
0 (0%)
Taking everything into account, ALIM scores 4 out of 10 in our fundamental rating. ALIM was compared to 191 industry peers in the Pharmaceuticals industry. ALIM may be in some trouble as it scores bad on both profitability and health. ALIM is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ALIM had negative earnings in the past year.
ALIM had a negative operating cash flow in the past year.
In the past 5 years ALIM always reported negative net income.
ALIM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -10.16%, ALIM is doing good in the industry, outperforming 72.82% of the companies in the same industry.
ALIM has a Return On Equity of -39.38%. This is in the better half of the industry: ALIM outperforms 62.05% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.12%, ALIM is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| ROIC | 0.12% |
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALIM has a Operating Margin of 0.20%. This is in the better half of the industry: ALIM outperforms 76.92% of its industry peers.
ALIM's Gross Margin of 86.39% is amongst the best of the industry. ALIM outperforms 90.26% of its industry peers.
In the last couple of years the Gross Margin of ALIM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.2% | ||
| PM (TTM) | N/A | ||
| GM | 86.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALIM is destroying value.
ALIM has more shares outstanding than it did 1 year ago.
ALIM has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.37, we must say that ALIM is in the distress zone and has some risk of bankruptcy.
ALIM's Altman-Z score of -1.37 is in line compared to the rest of the industry. ALIM outperforms 48.21% of its industry peers.
ALIM has a Debt/Equity ratio of 1.80. This is a high value indicating a heavy dependency on external financing.
ALIM has a worse Debt to Equity ratio (1.80) than 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.37 |
ROIC/WACC0.01
WACC9.95%
2.3 Liquidity
ALIM has a Current Ratio of 2.79. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.79, ALIM is in line with its industry, outperforming 45.13% of the companies in the same industry.
ALIM has a Quick Ratio of 2.62. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
ALIM's Quick ratio of 2.62 is in line compared to the rest of the industry. ALIM outperforms 49.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
ALIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.66%, which is quite impressive.
The Revenue has grown by 69.76% in the past year. This is a very strong growth!
ALIM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
3.2 Future
The Earnings Per Share is expected to grow by 22.30% on average over the next years. This is a very strong growth
ALIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.81% yearly.
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALIM. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 28.59, the valuation of ALIM can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALIM indicates a somewhat cheap valuation: ALIM is cheaper than 77.44% of the companies listed in the same industry.
ALIM's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALIM is valued a bit cheaper than the industry average as 77.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 28.66 |
4.3 Compensation for Growth
ALIM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALIM's earnings are expected to grow with 30.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%
5. Dividend
5.1 Amount
No dividends for ALIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.54
-0.01 (-0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change0%
Market Cap301.27M
Revenue(TTM)99.68M
Net Income(TTM)-15.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.59 | ||
| P/S | 3.02 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.66 |
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| ROCE | 0.15% | ||
| ROIC | 0.12% | ||
| ROICexc | 0.13% | ||
| ROICexgc | 0.56% | ||
| OM | 0.2% | ||
| PM (TTM) | N/A | ||
| GM | 86.39% | ||
| FCFM | N/A |
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.55 | ||
| Cap/Depr | 1.81% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 0.03 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | -1.37 |
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A
ALIMERA SCIENCES INC / ALIM FAQ
What is the fundamental rating for ALIM stock?
ChartMill assigns a fundamental rating of 4 / 10 to ALIM.
Can you provide the valuation status for ALIMERA SCIENCES INC?
ChartMill assigns a valuation rating of 3 / 10 to ALIMERA SCIENCES INC (ALIM). This can be considered as Overvalued.
Can you provide the profitability details for ALIMERA SCIENCES INC?
ALIMERA SCIENCES INC (ALIM) has a profitability rating of 3 / 10.
Can you provide the financial health for ALIM stock?
The financial health rating of ALIMERA SCIENCES INC (ALIM) is 3 / 10.
What is the expected EPS growth for ALIMERA SCIENCES INC (ALIM) stock?
The Earnings per Share (EPS) of ALIMERA SCIENCES INC (ALIM) is expected to grow by 94.02% in the next year.